Pituitary Cells Already Have the Machinery to Process Dynorphin Correctly
AtT-20 pituitary cells given the prodynorphin gene processed it correctly, including rare cleavage sites — showing all necessary processing enzymes are already present.
Quick Facts
What This Study Found
AtT-20 pituitary cells contain all the enzymes needed to process prodynorphin correctly, including at rare monobasic cleavage sites. The processed peptides were released in response to CRF stimulation.
Key Numbers
How They Did This
Rat prodynorphin cDNA was stably transfected into mouse AtT-20 cells. Peptide products were identified using gel filtration, reverse phase HPLC, and peptide-specific radioimmunoassays. Secretion was tested with CRF stimulation.
Why This Research Matters
This proved that pituitary cells have the full toolkit to process prodynorphin, even though they do not normally make it. It provided a lab model for studying how opioid peptides are made and released.
The Bigger Picture
This showed that peptide processing machinery is shared across different peptide families. Cells do not need special enzymes for each peptide — the processing system is universal.
What This Study Doesn't Tell Us
This was an in-vitro study using an engineered cell line. Processing in living brain tissue may differ. The cells already had a secretory pathway, which aided success.
Questions This Raises
- ?Can other cell types be engineered to produce therapeutic peptides?
- ?Could gene therapy deliver prodynorphin for pain treatment?
Trust & Context
- Key Stat:
- Universal processing machinery Cells that normally make POMC correctly processed foreign prodynorphin
- Evidence Grade:
- Preliminary in-vitro study using cell line transfection — clean results in controlled conditions.
- Study Age:
- Published in 1989 — demonstrated universality of peptide processing enzymes.
- Original Title:
- Expression and posttranslational processing of preprodynorphin complementary DNA in the mouse anterior pituitary cell line AtT-20.
- Published In:
- Molecular endocrinology (Baltimore, Md.), 3(11), 1852-60 (1989)
- Authors:
- Devi, L, Gupta, P, Douglass, J(2)
- Database ID:
- RPEP-00108
Evidence Hierarchy
Frequently Asked Questions
What does this mean for gene therapy?
If cells can correctly process foreign peptide genes, it is theoretically possible to engineer patients own cells to produce therapeutic peptides for conditions like chronic pain.
What are monobasic cleavage sites?
Rare single-amino-acid cut sites in precursor proteins. Most cuts occur at paired basic amino acids. The ability to cut at these rare sites shows sophisticated processing capability.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00108APA
Devi, L; Gupta, P; Douglass, J. (1989). Expression and posttranslational processing of preprodynorphin complementary DNA in the mouse anterior pituitary cell line AtT-20.. Molecular endocrinology (Baltimore, Md.), 3(11), 1852-60.
MLA
Devi, L, et al. "Expression and posttranslational processing of preprodynorphin complementary DNA in the mouse anterior pituitary cell line AtT-20.." Molecular endocrinology (Baltimore, 1989.
RethinkPeptides
RethinkPeptides Research Database. "Expression and posttranslational processing of preprodynorph..." RPEP-00108. Retrieved from https://rethinkpeptides.com/research/devi-1989-expression-and-posttranslational-processing
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.